A literature review identified CIPN as a potential contributor to falls and injuries in patients with cancer; however, evidence-based methods for preventing falls in these patients are scarce.
Researchers sought to determine if the complementary practice could prevent CIPN in patients receiving adjuvant chemotherapy for breast cancer.
Researchers sought to determine how subjective measures of CIPN correlated with objective measures of CIPN.
Research presented at the 2018 ONS Congress reported on the effectiveness of ESRA-C, a web-based assessment and self-care intervention program, in the management of CIPN in patients receiving platinum and/or taxane-based chemotherapy.
Self-guided online cognitive behavioral pain management may result in improved “worst” pain but not “average” pain compared with usual care for the treatment of painful chemotherapy-induced peripheral neuropathy.
Quality of life for patients with CIPN was improved by wearing frozen gloves during treatment. Researchers reported in an oral presentation at ESMO 2017 Congress that the gloves reduced symptoms even though long-term differences in neuropathy were not observed.
Breast cancer survivors who received taxane-based chemotherapy for their disease are at increased risk for falls due to CIPN and treatment-associated effects on balance and gait.
Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy. A new study identified gene variations that can predispose people to chemotherapy-induced peripheral neuropathy.
